139 completed, 45 unknown, 34 terminated, 32 active not recruiting. 137 Phase 2, 100 Phase 3, 30 Phase 1, 18 Phase 4, 16 Not applicable.
Follow Goserelin: new trials by email Literature Review of Goserelin trials Research Report on Goserelin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer ZOLADEX - Advanced Breast Cancer, Early Breast Cancer | Phase 1 | Recruiting | TerSera Therapeutics LLC | 176 | 2026-10-30 | 2026-10-13 |
| ADT De-escalation in Selected High-Risk Prostate Cancer Patients (ADaPPt Trial) a GROUQ Led PCS Study (PCS XIV) ZOLADEX 10.8 mg - High Risk Prostate Cancer | Phase 3 | Not yet recruiting | Dr. Tamim Niazi | 600 | 2026-10-01 | 2026-08-20 |
| QL1706 Plus Neoadjuvant Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer With a Poor Response to Neoadjuvant Chemotherapy Iparomlimab and Tuvonralimab (QL1706), Aromatase Inhibitor (AI), CDK4/6 inhibitor - Breast Cancer | Phase 2 | Not yet recruiting | Hebei Medical University Fourth Hospital | 40 | 2026-10-01 | 2026-08-26 |
| BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder Aromatase Inhibitors, Bupropion, GnRH agonist - Early-stage Breast Cancer, Hypoactive Sexual Desire Disorder | Phase 1 / Phase 2 | Not yet recruiting | University of Illinois at Chicago | 100 | 2026-09-01 | 2026-08-24 |
| Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate Cancer Abiraterone, Apalutamide, Enzalutamide or Darolutamide (ARPI therapy) (per standard of care) therapy - Prostate Cancer, mHSPC | Phase 3 | Recruiting | University College, London | 1500 | 2026-08-28 | 2026-10-16 |
| Evaluation of Alternative Site Goserelin Acetate Injection for Ovarian Function Suppression (OFS) in Local and Locally Advanced Premenopausal Hormone Receptor Positive Breast Cancer Patients Biospecimen Collection, Goserelin Acetate, Questionnaire Administration - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8 | Phase 2 | Recruiting | Mayo Clinic | 98 | 2026-05-22 | 2026-10-01 |
| A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer Imlunestrant, Goserelin, Tamoxifen 20 mg - Breast Neoplasms | Phase 2 | Recruiting | Eli Lilly and Company | 600 | 2026-05-13 | 2026-10-08 |
| Clinical Study on the Preservation of Ovarian Function Following Hematopoietic Stem Cell Transplantation in Patients With Malignant Hematologic Diseases Using Goserelin Goserelin - Allogeneic Haematopoietic Stem Cell Transplantation, Malignant Hematologic Disease | Not applicable | Not yet recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 64 | 2026-05-01 | 2026-04-27 |
| Clinical Study on the Preservation of Ovarian Function Following Autologous Hematopoietic Stem Cell Transplantation Using Goserelin Goserelin 3.6 MG - Ovarian Insufficiency, Autologous Hematopoietic Stem Cell Transplantation | Not applicable | Not yet recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 64 | 2026-05-01 | 2026-04-27 |
| Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial Biospecimen Collection, Electronic Health Record Review, Goserelin - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8 | Phase 2 | Recruiting | University of Michigan Rogel Cancer Center | 75 | 2026-01-22 | 2026-06-23 |
| Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study Trastuzumab rezetecan, Pyrotinib, Dalpiciclib - HER2-positive Breast Cancer | Phase 2 | Not yet recruiting | Fudan University | 288 | 2025-09-10 | 2025-09-18 |
| The COSMYC Trial (COmbined Suppression of MYC) ZEN-3694, Testosterone cypionate, Enzalutamide - Metastatic Castration-resistant Prostate Cancer | Phase 2 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 50 | 2025-08-19 | 2026-06-18 |
| A Study to Assess the Bioequivalence of Follitropin Alfa Solution in Pen and Follitropin Alfa Powder in Vial in Healthy Downregulated Male Participants Test: Follitropin alfa, Reference: Follitropin alfa, Zoladex - Hypogonadism | Phase 1 | Completed | EMD Serono Research & Development Institute, Inc. | 55 | 2025-07-21 | 2026-02-24 |
| Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy Ribociclib 400mg, Letrozole 2.5mg, Anastrazole 1mg - HER2 Negative Breast Cancer | Phase 2 | Recruiting | Yale University | 140 | 2025-07-09 | 2026-05-26 |
| Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer Gonadotropin Releasing Hormone Agonists and Antagonists, Bicalutamide, Biopsy Procedure - High Risk Prostate Carcinoma, Localized Prostate Adenocarcinoma | Phase 2 | Withdrawn | OHSU Knight Cancer Institute | 2025-04-16 | 2025-09-23 | |
| Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery Trastuzumab emtansine, Pertuzumab Injection, Docetaxel - Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, HER2-positive Breast Cancer | Phase 2 | Recruiting | University of Chicago | 74 | 2025-03-18 | 2026-02-17 |
| Effect of a GnRH Analog on Hepatic Steatosis Goserelin Acetate 3.6 mg inj, implant - Metabolic Dysfunction-Associated Steatotic Liver Disease, Nonalcoholic Fatty Liver | Phase 4 | Active not recruiting | Aristotle University Of Thessaloniki | 62 | 2024-11-26 | 2026-07-23 |
| Artificial Intelligence to Personalize Prostate Cancer Treatment (the HypoElect Trial) Androgen Deprivation Therapy (ADT) - Goserelin, High-Dose-Rate Interstitial Brachytherapy (HDR BRT), radiotherapy - Prostate Cancer | Phase 2 | Recruiting | German Oncology Center, Cyprus | 30 | 2024-09-16 | 2026-09-17 |
| Adaptions and Resiliency to Multi-Stressor OpeRations Goserelin 3.6 MG, Multi-Stressor Training, Testosterone gel (AndroGel 5g) - Musculoskeletal Injury, Hypogonadism | Phase 4 | Recruiting | Bradley Nindl | 120 | 2024-07-15 | 2026-08-18 |
| Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial Abiraterone, Apalutamide, Biospecimen Collection - Recurrent Castration-Sensitive Prostate Carcinoma, Recurrent Prostate Cancer | Phase 2 | Recruiting | Mayo Clinic | 532 | 2024-06-03 | 2026-07-20 |
Showing 20 of 297. Sign in to see all of them.
Prostatic Neoplasms (140) · Breast Neoplasms (96) · Neoplasms (8) · Neoplasm Metastasis (7) · Breast Neoplasms, Male (6) · Endometriosis (6) · Infertility (4) · Hypogonadism (3) · Metabolic Syndrome (3) · Recurrence (3) · Salivary Gland Neoplasms (3) · Bulbo-Spinal Atrophy, X-Linked (2) · Infertility, Male (2) · Insulin Resistance (2) · Leiomyoma (2)
National Cancer Institute (NCI) (13) · Novartis Pharmaceuticals (12) · AstraZeneca (9) · M.D. Anderson Cancer Center (9) · Fudan University (7) · Radiation Therapy Oncology Group (7) · SWOG Cancer Research Network (7) · Ferring Pharmaceuticals (6) · University of Washington (6) · Luye Pharma Group Ltd. (5) · Mayo Clinic (5) · UNICANCER (5) · Washington University School of Medicine (5) · Alliance for Clinical Trials in Oncology (4) · Memorial Sloan Kettering Cancer Center (4)
United States (134) · China (43) · Canada (31) · Germany (20) · United Kingdom (20) · Belgium (17) · France (16) · Japan (12) · South Korea (12) · Spain (12) · Taiwan (12) · Italy (11) · India (10) · Mexico (10) · Finland (9)
Christopher Logothetis (3) · Frances J Hayes, MD (3) · Carlos Vargas, MD (2) · Cynthia X Ma, M.D., Ph.D. (2) · George Wilding, MD (2) · Jacqueline Vuky, MD (2) · Jonas Bergh, Professor (2) · Mary-Ellen Taplin, MD (2) · Michel Bolla, MD (2) · Nancy A. Dawson, MD (2) · R. Bruce Montgomery, MD (2) · Raimund Jakesz, MD (2)
PMID 34350976, PMID 38320143, PMID 38421243, PMID 20818327, PMID 23533230, PMID 25592642, PMID 36596347, PMID 42334791, PMID 10663329, PMID 12126818, PMID 12160582, PMID 12743142, PMID 14581419, PMID 15169799, PMID 15251156, PMID 15315996, PMID 16323171, PMID 16921051, PMID 16979837, PMID 17011443, PMID 17405995, PMID 17405996, PMID 17498886, PMID 17531401, PMID 17575222, PMID 17634487, PMID 17689883, PMID 17881290, PMID 17918264, PMID 18037582, PMID 18212313, PMID 18243498, PMID 18291508, PMID 18309951, PMID 18314175, PMID 18349405, PMID 18413638, PMID 18779620, PMID 18989865, PMID 19012911, PMID 19167733, PMID 19211454, PMID 19395184, PMID 19395186, PMID 19470936, PMID 19682889, PMID 19706804, PMID 19858385, PMID 19864082, PMID 19957321
2008 (5), U10CA032102 (5), P30CA015083 (4), U10CA180868 (4), U10CA031946 (3), U10CA180820 (3), 2014 (2), 2016 (2), P30CA008748 (2), P30CA016672 (2), P30CA033572 (2), U10CA021115 (2), 2005 (1), 2009 (1), 2017 (1)